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Abstract
Understanding the mechanisms of migraine remains challenging as migraine is not a static disorder, and even in
its episodic form migraine remains an “evolutive” chronic condition. Considerable progress has been made in
elucidating the pathophysiological mechanisms of migraine, associated genetic factors that may influence
susceptibility to the disease, and functional and anatomical changes during the progression of a migraine attack
or the transformation of episodic to chronic migraine. Migraine is a life span neurological disorder that follows an
evolutive age-dependent change in its prevalence and even clinical presentations. As a disorder, migraine involves
recurrent intense head pain and associated unpleasant symptoms. Migraine attacks evolve over different phases
with specific neural mechanisms and symptoms being involved during each phase. In some patients, migraine can
be transformed into a chronic form with daily or almost daily headaches. The mechanisms behind this evolutive
process remain unknown, but genetic and epigenetic factors, inflammatory processes and central sensitization may
play an important role.
Introduction
Migraine is a recurrent, disabling neurological disorder,
involving intense head pain and associated with other
unpleasant symptoms. Migraine affects about 15% of the
general population [1] and causes substantial personal
suffering and impaired quality of life with a significant
socioeconomic impact. The toll of chronic migraine on
individual and society is even bigger, as up to 45% of pa-
tients presenting to headache clinics have daily or near-
daily headaches [2, 3], with nearly half of them in need
of a migraine preventive treatment [4]. The World
Health Organization ranks migraine as the most preva-
lent, disabling, long-term neurological condition when
taking into account years lost due to disability [5].
Considerable progress has been made in elucidating
the pathophysiological mechanisms of migraine, associ-
ated genetic factors that may influence susceptibility to
the disease and functional and anatomical changes dur-
ing the progression of a migraine attack, or the trans-
formation of episodic to chronic migraine. However,
understanding disease mechanisms remains challenging
as migraine is not a static disorder, and even in its epi-
sodic form migraine remains an “evolutive” chronic
condition.
Migraine as a life span disorder
Migraine is a life span disorder affecting children, adults
and the elderly. The clinical presentation of migraine
shows an age-dependent change with shorter duration
and also occurrence of special paroxysmal symptoms
like vomiting, abdominal pain or vertigo in childhood
and largely an absence of autonomic signs in the elderly.
The prevalence of migraine in children varies, depend-
ing on the study and the age range of the included sub-
jects, between 2.7% and 10.0% and in younger children
(below 7 years) it does not differ between girls and boys
[6, 7]. In adulthood, migraine is more prevalent in
women than in men with a lifetime prevalence of 12–17%
and 4–6%, respectively [8, 9]. A factor that may contribute
to the increased prevalence of migraine in women
compared to men in the reproductive years is estrogen
withdrawal which is a reliable trigger of menstrual attacks
in women [10]. Migraine in women usually declines
after menopause [11, 12], indicating further the influ-
ence of hormonal changes on migraine occurrence.
The prevalence of migraine in the elderly is about
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3.5% with females affected ~ 2 times more often than
males [13, 14].
The clinical manifestation of migraine is different in
childhood from that in adulthood. Pediatric migraine is
characterized by shorter attacks with the pain being less
often unilateral. Accompanying symptoms include mild
intolerance to light and rarely to noise [15], while vomit-
ing and cranial autonomic features are significantly more
frequent compared to adult patients [16, 17].
Beyond the influence of hormonal changes in women
that can be partially responsible for the changes in the
prevalence of migraine in adults and the elderly, another
general feature seems to be a decrease in autonomic
symptoms during aging. All these symptoms are associ-
ated with increased parasympathetic activity. A possible
explanation is a change in the connectivity of hypothal-
amic areas to different autonomic control centres during
aging in migraine [18]. Readers interested in changes in
migraine symptoms during lifespan, as well as, in mecha-
nisms that may be driving these changes, are encouraged
to read a recent review by Straube and Andreou [18].
Genetic and epigenetic component of migraine
Genetic factors may determine susceptibility to migraine,
while different environmental factors can contribute to
the development of a migraine attack [19, 20]. Mainly
through genome-wide association studies (GWAS), which
tested for differences in allele frequencies of single nucleo-
tide polymorphisms (SNPs) over the genome in migraine
patients and controls [21], it is now understood that mul-
tigenetic variants, rather than individual genes, influence
the susceptibility to migraine. Although GWAS in mi-
graine, similarly to other disorders studied with GWAS
[22], failed to shed light on the molecular changes that are
responsible for the evolutive nature of migraine, one can
envisage that combined knowledge from many variants
will highlight which molecular pathways potentially could
be involved in migraine pathophysiology [20].
In the latest GWAS which included samples from nearly
60, 000 patients and over 300,000 controls, 44 SNPs were
associated with migraine without aura, implicating 38 dis-
tinct genomic loci [23]. The majority of them were found
to be implicated in molecular pathways related to vascular
function. Other loci identified in this study, were involved
in pathways related to metal ion homeostasis, leading to a
rather unexpected, hypothesis that metal ion homeostasis
might contribute to migraine susceptibility. Only a hand-
ful of loci was found to be involved in ion channel activity,
with much less prominent signals [20]. The importance of
those compared to the outcomes related to vascular func-
tion, remains a matter of debate, as this study highlighted
that vascular dysfunction is of great importance in mi-
graine susceptibility with neuronal dysfunction playing a
rather secondary role [20].
Regardless of these outcomes, due to their small effect
size no single SNP has any clinical use in predicting the
risk of developing migraine. There is still a big challenge
in the field of GWAS to link associated SNPs to actual
genes and pathways. GWAS in migraine are yet to offer
further knowledge on the functional consequences of
the associated SNPs and how they influence susceptibil-
ity to migraine.
On the other hand, genetic studies of hemiplegic mi-
graine, a rare monogenic forms of migraine [24] offered
knowledge about specific genes that encode proteins in-
volved in the function of ion channels and transporters.
Specific mutations in these genes were studied in de-
tailed and were shown to induce either loss or gain of
function in cellular assays or in mutant murine. In brief,
mutations involved in familial hemiplegic migraine were
found in the genes CACNA1A, ATP1A2 and SCN1A,
which encode subunits of neuronal voltage-gated CaV2.1
Ca2+, NaV1.1 Na
+ channels, and glial Na+K+ ATPases,
respectively. Interestingly a common consequence of
these mutations is an increase in glutamate availability
at the synaptic cleft of cells. Mutations in the CACNA1A
gene can have as a consequence enhanced glutamate re-
lease due to enhanced calcium flux at the presynaptic
terminal [25]. Mutations in the ATP1A2 gene result in a
smaller electrochemical gradient for Na+. One effect of
this is the reduction or inactivation of astrocytic glutam-
ate transporters, leading to a build-up of synaptic
glutamate [26]. The SCN1A mutations can result in fa-
cilitation of high-frequency discharges that might also
increase synaptic glutamate levels [27]. Thus, the neu-
rons at glutamatergic synapses can fire at a higher fre-
quency than they do under normal conditions and this
might explain the increased susceptibility to cortical
spreading depression, the underlying mechanism of mi-
graine aura [28, 29]. Interestingly, mice carrying the
CACNA1A mutation exhibit blunted trigeminovascular
nociceptive responses and calcitonin gene-related peptide
(CGRP) expression [30, 31].
Although genetic factors may be involved in the evolu-
tive processes of migraine, to date they failed to explain
the pathophysiology of migraine and evolutive mecha-
nisms. However, it is important to mention the know-
ledge gained from such studies, as they are part of
disease mechanisms and disease susceptibility, while in
the future they may be able to explain better the mecha-
nisms that transform migraine into a chronic form in
some individuals or achieve migraine freedom altogether
later in life.
Is there a role for epigenetic mechanisms in migraine
susceptibility and chronification?
Beyond genetic factors that could be responsible for
migraine susceptibility and evolution to migraine
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chronification, epigenetic pathways through changes in
DNA expression could also influence an individual’s sen-
sitivity to migraine. Epigenetics refers to modification of
gene expression without altering the underlying DNA
sequence. A main epigenetic mechanism is DNA methy-
lation, the covalent addition of a methyl group to the
fifth carbon of cytosine residues, which is typically asso-
ciated with gene silencing. The cause of epigenetic
changes in not well understood, but it can include envir-
onmental factors, early life events, inflammation, stress
and brain plasticity.
Epigenetics is a new area of research and only a hand-
ful of studies are done in migraine patients. Recently,
the first genome-wide study of DNA methylation in
headache chronification was published [32]. Although,
several potentially implicated loci and processes were
identified, only in the combined meta-analysis statistical
significance was found for two CpG sites which were re-
lated to two brain-expressed genes; SH2D5 and NPTX2.
The H2D5 gene encodes the SH2 domain-containing 5
protein which is thought to regulate indirectly synaptic
plasticity through the control of Rac-GTP levels. The
NPTX2 gene encodes the neuronal pentraxin II protein,
an inhibitor of excitatory synapses, through binding and
clustering of glutamatergic AMPA receptors. Both pro-
teins are highly expressed in the adult human brain [32].
A smaller pilot study aimed to identify changes in
DNA methylation associated with headache chronifica-
tion by characterising genome-wide DNA methylation
levels in episodic migraineurs and patients suffering
from chronic migraine with medication overuse head-
ache (MOH), before and after detox programme. Al-
though no statistical significance was found between the
groups at different time points, some CpG sites of inter-
est were identified, and are thought to be involved in
drug addiction mechanisms and neuropsychiatric illness
comorbid [33].
These preliminary data seem to support a role of epi-
genetic processes migraine, and theoretically they could
be involved in mechanisms of brain plasticity and other
migraine-specific processes. However, considering that
migraine, both in its episodic and chronic form, is a
complex and multidimensional disorder, all these pre-
liminary data require replication and validation in much
larger samples.
Brain changes in the migraineur: is it a brain evolutive
process?
Beyond functional changes, differences in the structural
brain integrity, involving both the white and gray matter,
which evolve over time, have been reported by several
studies between migraine patients and controls.
The prevalence and volume of deep white matter le-
sions is increased in migraine patients, with women with
migraine with aura having the highest prevalence
[34–36]. Interestingly, these white matter lesions are
not static and their development involves a gradual
process for the evolution of focal invisible microstructural
changes into focal migraine-related visible white matter le-
sions [37]. Later studies showed long-term higher inci-
dence of deep white matter brain changes, especially
among female patients. These changes were related to an
increased number of new lesions rather than an increase
in the size of pre-existing lesions [38]. In the ARIC MRI
study [39], the authors showed that although migraine has
an increased insistence of white matter lesions, there is no
progression overtime. The authors suggest that the associ-
ation between migraine and white matter lesions is stable
in older age and may be attributable to changes occurring
earlier in life [39]. Indeed, although white matter lesions
are not as prevalent in children, they are not unusual
[40–42]. Whether these early life changes are attrib-
uted to genetic factors, remains to be established,
however, the outcomes of the GWAS on vascular fac-
tors that may contribute to migraine susceptibility,
may also suggest an increased susceptibility to white
matter lesions.
A number of studies showed cortical structural
changes in migraine patients (detail reviews can be
found here [43–47]. To this end there are conflicting re-
sults to whether there is cortical thinning or cortical
thickening in the migraineur’s brain. Such changes in-
clude, increased thickening in the somatosensory cortex
of patients with migraine that does not differ between
patients with and without aura, decreased grey matter in
cingulate cortex and reduced volume of the medial pre-
frontal cortex, atypical age-related cortical thinning in
episodic migraine, increased thickness of the left middle
frontal sulcus and the left temporo-occipital incisure, as
well as, reduced thickness of the left superior frontal
sulcus and the left precentral sulcus [48–52]. A more re-
cent multi-centre 3 T MRI study utilising a large number
of migraine patients [53] demonstrated significant
clusters of thinner cortex in the patients with migraine
compared with control subjects [54].
Gray matter changes have been reported in the region
of the thalamus and a reduced striatal volume in mi-
graine subjects with and without aura. Studies have
shown broad microstructural alterations in the thalamus
of migraine patients that may underlie abnormal cortical
excitability. These changes involve reduced volume in
thalamic nuclei with dense connections to the limbic
system, including the central nuclear complex, anterior
nucleus and lateral dorsal nucleus [55, 56]. Migraineurs
were also found to have structural alterations of the
brainstem with significant inward deformations in the
ventral midbrain and pons, and outward deformations in
the lateral medulla and dorsolateral pons [57].
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An interesting study by Coppola and colleagues dem-
onstrated that structural changes in the brain of episodic
migraine patients without aura evolve over the course of
the migraine cycle. Interictally, patients were shown to
have a significantly lower gray matter density within the
right inferior parietal lobule, right temporal inferior
gyrus, right superior temporal gyrus, and left temporal
pole when compared to healthy controls. Ictally, gray
matter density increased within the left temporal pole,
bilateral insula, and right lenticular nuclei, but no areas
exhibited decreased density. The authors suggested that
these morphometric changes between ictal and interictal
phases indicate abnormal structural plasticity [58].
Whether these changes are an important mechanism of
migraine pathology remains to be evaluated. If indeed
these data can be reproduced, they demonstrate that
evolutive processes happen in the migraineur’s brain
constantly and in a cycling manner.
In CM patients, white-matter abnormalities were found
in the brainstem and cerebellum [59]. Other studies
showed, that CM is associated with subtle gray matter
volume changes in several brain areas known to be in-
volved in nociception/anti-nociception, multisensory inte-
gration, and analgesic dependence [60, 61]. Gray matter
changes, have been reported to correlate with headache
frequency assessed in both episodic and chronic migraine
[60]. Recently, another study demonstrated alterations in
the region of the hypothalamus, with the volume of the
hypothalamus being significantly decreased in both epi-
sodic and chronic migraine patients, which in CM was
positively correlated with headache frequency [62]. Bigger
longitudinal volumetric neuroimaging studies with larger
groups, especially on the chronification of migraine, are
needed to understand the evolutive nature of these
changes.
What causes these structural changes in the migraine
brain is not known. Some alterations may be due to a
genetic susceptibility towards developing migraine at-
tacks. To this end, structural brain studies in paediatric
migraine patients, could shed more light in the cause of
this structural changes. A small MRI study showed
significant alterations in brain volume. Compared to
controls, paediatric migraine patients experienced a sig-
nificant gray matter loss in several areas of the frontal
and temporal lobes which are part of the pain-
processing network, while they had increased gray mat-
ter volume of the right putamen. Between patients with
aura compared to patients without aura, the left fusiform
gyrus had an increased volume. In the paediatric popula-
tion of migraine these structural changes were not corre-
lated with disease duration and attack frequency [63]. A
more recent study that used MRI apparent diffusion co-
efficient (ADC) found no volumetric changes in paediat-
ric migraine patients, but demonstrated increased ADC
in the region of the hippocampus, brain stem and the
thalamus [64]. Although these studies used a smaller
number of patients, data suggest that brain abnormalities
do occur early on in migraine patients and the absence
of correlation with patient clinical characteristics suggest
that they may represent a phenotype developed as a con-
sequence of genetic susceptibility.
Other changes could be a consequence of repeated
head pain attacks. Such structural changes can be the re-
sult of brain plasticity, which is defined as the ability of
the brain to modify its own structure and function fol-
lowing changes within the body or in the external envir-
onment. A number of CNS changes can contribute
towards gray matter changes, such as synaptogenesis,
angiogenesis, glia genesis, neurogenesis, increase in cell
size, increase in myelin size and increase in blood flow
or interstitial fluid. White matter changes are usually the
result of axonal remodelling and changes in blood flow
[65]. Despite the number of reports of structural changes
in the migraineur’s brain, their importance in the biology
of migraine remains uncertain. Nevertheless, the exist-
ence of structural changes, suggest that migraine induces
progressive anatomical transformation in the brain that
may have an evolutive role in disease progression and
associated disability.
The evolutive migraine attack
Migraine is cyclic disorders with a complex sequence of
symptoms within every headache attack. In its episodic
form, migraine is characterised by recurrent attacks in-
volving different phases: (a). A premonitory phase prior
to the onset of the actual headache, characterised by
symptoms, such as excessive yawning, thirst, somno-
lence, food craving, cognitive difficulties, and mood
changes [66] (b). Transient neurological symptoms,
known as migraine aura (typically visual alterations), that
occur just before the actual headache starts [67]. (c). An
intense headache attack, usually involving only one site
of the head, which can be exacerbated by movement and
accompanied with hypersensitivity to sensory stimuli
(e.g. light and smells), nausea [68]. (d) The postdrome
phase which is mainly characterised by symptoms of fa-
tigue, difficulties in concentration and comprehension,
and neck stiffness [69]. During the interictal phase, al-
though patients may appear normal, genetic predispos-
ition and a number of triggers make them susceptible to
an attack.
Several factors may trigger migraine; stress and lack of
sleep are probably the most common [70]. Significant
advances have been made in characterising migraine as a
brain disorder and in identifying evolutive functional
changes in different brain areas during the different
phases of a migraine attack (Fig. 1). However, despite
the number of studies on pain pathways involved during
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the headache phase [71], the molecular changes that ac-
tually trigger a migraine attack in the brain remain un-
known. The lack of such knowledge had significantly
hampered the design of migraine-specific and effective
preventive treatments for a long time. Emerging evi-
dence, partly obtained through use of the newly designed
migraine treatments designed against the calcitonin
gene-related peptide (CGRP) and its receptors [72], fur-
ther highlights an important role of the trigeminal sys-
tem in driving migraine attacks.
The premonitory phase and the triggering mechanisms of
migraine
Accumulating evidence exists as to why the trigger of
migraine attacks should be sought in the hypothalamus.
The hypothalamus is a small brain structure, consisted
by a number of different nuclei with distinct neuro-
pharmacology and function. Its multitude of functions
can, in a broader sense, be described as functions that
organise the circadian rhythms, control and maintain
the homeostasis and regulate arousal [73].
Migraine onset appears to have a circadian rhythmi-
city. Migraine attacks tend to occur in a daily, monthly
or even seasonal pattern, further suggesting a role for
hypothalamic areas, responsible for the entrained bio-
logical clock-function, in the development of the disease
[74, 75]. Morphological and functional gender differ-
ences in several nuclei of the hypothalamus, may be also
responsible for the monthly, menstrual associated mi-
graine attacks, and the increased prevalence of migraine
in women (~ 3:1) [76].
The premonitory symptoms of migraine are strongly as-
sociated with homeostatic functions regulated by the
hypothalamus, such as arousal, sleep and feeding. The
strongest, direct evidence for hypothalamic activation in
migraine patients arises from brain imaging studies. These
studies demonstrated, using positron emission tomog-
raphy, increased blood flow in the region of the hypothal-
amus during the very early stages of spontaneous
migraine attacks [77, 78] and during the premonitory
phase of nitroglycerin (nitric oxide-NO donor)-induced
migraine attacks [79].
A disturbance in homeostatic function is a significant
trigger of attacks [70]. Sleep/arousal physiology in par-
ticular, deserves greater attention as sleep disturbances
can trigger attacks in over 50% of migraine sufferers.
Additionally, patients with both episodic and chronic
migraine are more prone to have their attacks in the
morning [80]. Morning headaches are also common in
patients with sleep disorders, while post-operative mi-
graine attacks in patients are common following anaes-
thesia [81]. Importantly, sleep itself has a striking effect
Fig. 1 Migraine is cyclic disorders with a complex sequence of symptoms within every headache attack. In its episodic form, migraine is
characterised by recurrent attacks involving different phases, with a complex sequence of symptoms within every phase. Significant advances
have been made in characterising migraine as a brain disorder and in identifying evolutive functional changes in different brain areas during the
different phases of a migraine attack
Andreou and Edvinsson The Journal of Headache and Pain          (2019) 20:117 Page 5 of 17
as an abortive strategy [82], particularly for the majority
of patients who find no relief by pharmacological treat-
ments. The discovery of a mutation in the clock-gene
CK1δ, causing so called familiar advanced sleep phase
syndrome, was strongly linked to migraine both clinically
and experimentally in mice engineered to carry this mu-
tation [83]. The increased comorbidity of migraine in
narcolepsy [84] and sleepwalking [85], also supports that
migraine is an arousal-related disorder.
Such evidence highlights that the posterior region of the
hypothalamus containing the circuitry for governing
arousal and the transition between sleep and wake, has a
key role in the triggering of migraine. However, which
hypothalamic nuclei, neurotransmitters and through
which mechanisms, may be implicated has not been inves-
tigated. Although several neurochemical pathways may be
involved in migraine pathophysiology [86], of them, dopa-
minergic mechanisms appear to play some role, as
yawning, a dopaminergic-driven function, is a prevalent
symptom during the premonitory phase of migraine. In
animal models the dopaminergic A11 nucleus of the
hypothalamus has been shown to project to the trigemino-
cervical complex [87], an important relay system involved
in migraine, and to modulate activation of the ascending
trigeminothalamic pathway [88, 89]. Additionally, the A11
nucleus has been shown to be susceptible to nitric oxide
donors in animal models of migraine [90, 91].
Of interest, an fMRI study of daily brain scans in a mi-
graine patient reported a strong association for both hypo-
thalamic and cortical activity during the premonitory
phase of an attack [78]. The involvement of the occipital
cortex in migraine has been long recognised, in particular
because of the visual aura phenomenon. Electrophysio-
logical studies and studies using transcranial magnetic
stimulation, suggest that migraineurs have altered cortical
activity, with the cortex, particularly the occipital region,
appearing hyperactive [92, 93]. A study of photophobia
during spontaneous migraine attacks using PET imaging
also found that this migraine symptom is linked with vis-
ual cortex hyperexcitability [94, 95]. It has been suggested
that thalamo-cortical dysrhythmia in migraine patients
may be responsible for abnormal cortical responses [96].
Hence, a focal cortical treatment for migraine without sys-
temic side effects is an attractive treatment opportunity.
To this end, single pulse TMS (sTMS) has been shown to
supress activation of the ascending trigemino-thalamic
pathway [97] and is now an approved migraine treatment
with good efficacy in the acute and preventive treatment
of migraine [98–100].
The migraine aura
Migraine with aura symptoms are typically seen in about
15–20% of patients [101] and usually they develop grad-
ually over 15–20min and last less than 60 min [68]. It is
now believed that the aura is the result of so called cor-
tical spreading depression (CSD) [102]. fMRI studies that
tried to capture or simulate aura in migraine patients
also pointed to a role for CSD as a mechanism for mi-
graine aura [103, 104]. CSD is a wave of cortical neur-
onal depolarisation, linked with depressed neuronal
activity and blood flow changes [105], which in migraine
is believed to spread out from the occipital cortex. In an-
imals, CSD is an NMDA-receptor depended process and
can be induced by cortical stimulation [106]. It remains
enigmatic how CSD is triggered in patients during mi-
graine aura. Potentially, if indeed cortex is hyperactive in
patients, this hyperactivity could trigger a CSD in certain
susceptible patients. As previously mentioned genetic
predispositions and environmental factors may modulate
individual susceptibility by lowering the CSD threshold
and cortical excitation may cause sufficient elevation in
extracellular K+ and glutamate to initiate CSD [26]. Of
interest, blood flow changes suggest a functional role for
the cortex and this has also been recorded in migraine
patients without aura [102].
The discussion of CSD-induced headache in migraine is
still a matter of debate, as not every migraine patient expe-
riences migraine aura, while the occurrence of aura with-
out a headache is not uncommon [107]. In experimental
animal modes, CSD was shown to induce edema, reflex
middle meningeal vasodilation and increases neural activ-
ity in the ipsilateral trigeminal ganglion and trigeminal
nucleus [108–111]. It was demonstrated that the trigemi-
nal activation produced by experimental CSD may cause
inflammation in the meninges that occurs after the CSD
has subsided [112]. Contradicting preclinical data to these
previous findings also exists [113, 114]. An alternative hy-
pothesis suggests that CSD activates cortico-thalamic fi-
bres that in turn sensitize third order neurons of the
ascending trigemino-thalamic pathway [115].
The headache phase
The headache phase of migraine involves activation of
the ascending trigeminothalamic pathway. Through early
observations in humans who underwent awake brain
surgery, it became well established that the pain during
a migraine attack is perceived to be felt on intracranial
structures, such as, the dura matter and intracranial vas-
culature [116]. The sensory innervation of these struc-
tures arises from the trigeminal nerve, mainly from
unmyelinated C-, and thinly myelinated Aδ-fibres, which
have their cell bodies in the trigeminal ganglion. Noci-
ceptive activation of the trigeminal fibres is referred to
as “trigeminovascular activation”. The trigeminal fibres
that transmit sensory information from such intracranial
structures synapse on second-order neurons within the
trigeminocervical complex (TCC; trigeminal nucleus
caudalis, C1 and C2 spinal levels). These neurons give
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rise to the main ascending trigemino-thalamic pathway
that relays sensory information to third order neurons,
mainly in the contralateral thalamus, before processing
the information to higher cortical areas.
The thalamus is a pivotal nucleus for multisensory in-
tegration and may be a strong candidate for influencing
neuronal excitability in migraine. The thalamic area is a
prominent site of action of triptans [117], of clinically
active preventives [118, 119] and of other potential anti-
migraine compounds [120]. Neuroimaging and electro-
physiological studies have revealed altered network
connectivity between the thalamus and pain modulating/
pain encoding cortical areas during spontaneous mi-
graine attacks, as well as, thalamo-cortical dysrhythmia
which correlate with migraine symptoms [121, 122].
Recently, a dynamic functional connectivity study in mi-
graine patients between attacks demonstrated abnormal
thalamo-cortical network dynamics, with the medial and
posterior thalamic nuclei identified in intrinsic subcor-
tical connectivity networks [123]. The role of the thal-
amus in migraine deserves higher attention given its
involvement in the development of associated symptoms,
such as hypersensitivity to visual stimuli [124], while
thalamo-cortical activation may also participate in the
development of auditory sensitivity [125]. Furthermore,
sensitization of third order thalamic neurons has been
implicated in the development of non-cranial allodynia
that is frequently seen in migraine patients [126].
A complex of descending networks from multiple
brainstem, midbrain and cortical nuclei modulate the ex-
citability of the ascending trigemino-thalamic pathway
[127]. In the absence of any evidence of malfunction in
the peripheral trigeminovascular system, a disruption of
normal endogenous descending modulatory tone may
play a critical role in migraine. To this end, a number of
brain imaging studies showed increased blood flow in
the region of the dorsal rostral pontine and brainstem in
both episodic [128, 129] and chronic migraine patients
[130]. A great limitation of brain imaging to date, is the
lack of spatial resolution. Hence, it remains a lot of fu-
ture research to delineate which descending networks
and neurotransmitters that potentially are involved. Can-
didate nuclei include the periaqueductal gray, locus
coeruleus, dorsal raphe nucleus and nucleus raphe mag-
nus. Initially, these loci were considered as the migraine
generator, due to the persistent blood flow increased in
the rostral pontine area following headache relief [131].
However, the increased blood flow in this region may be
expected given the role of the brainstem in descending
modulatory control of pain. What is interesting is that
functional connectivity fMRI studies between attacks,
have identified numerous brain regions and functional
networks with atypical functional connectivity in migrai-
neurs, and demonstrated interictal impairment of the
descending pain modulatory circuits, potentially indicat-
ing a reduction of pain inhibition in migraineurs [53].
The puzzle of migraine pathophysiology is still incom-
plete, as we are yet to understand how hypothalamic
dysfunction may lead to activation of the ascending tri-
geminothalamic pathway (Fig. 2). Activation of indirect
pathways, involving brainstem nuclei as discussed above
may indeed be a possibility. Alternatively, pathways
arising from the hypothalamus that project directly to
the TCC or the sensory thalamus, such as the dopamin-
ergic A11 nucleus or the histaminergic tuberomammil-
lary nucleus, both located in the posterior region of the
hypothalamus, may directly alter the function of the as-
cending trigeminothalamic pathway.
An equally important pathway may be the trigeminal
autonomic activation in migraine driven by the hypo-
thalamus. Although autonomic features in migraine are
not as prominent as in trigeminal autonomic cephalal-
gias, increased parasympathetic activity signs can be fre-
quent [132]. Clinical evidence suggest that subjects with
cranial autonomic symptoms have a hyperactive efferent
arm of trigeminal autonomic reflex [132]. The hypothal-
amus is regulating the autonomic system and may in-
deed drive indirectly activation of the trigeminal system
through the trigeminal-autonomic arc. The vast majority
of parasympathetic fibers innervating the cerebral blood
vessels originate from the sphenopalatine and the otic
ganglia [133]. Sphenopalatine ganglion block in migraine
patients with autonomic features was found to relieve
the pain intensity by over 50% [134]. These findings sug-
gest that increased parasympathetic tone contributes to
the activation of perivascular nociceptors contributing
significantly to the pain intensity and possibly to the
initiation of central sensitization [135]. This could also
explain a brain-driven activation of the peripheral tri-
geminal system and the release of CGRP from trigeminal
fibers and cells located in the trigeminal ganglion. The
increased cranial parasympathetic outflow and modula-
tion of the trigeminal autonomic reflex by the hypothal-
amus in migraine may be of great importance.
The trigeminal system and its role in sustaining the
head pain in migraine Despite the various evidence of
increased blood flow changes in different brain nuclei
before or during the onset of the headache phase, what
really alters the excitability of the ascending trigemino-
thalamic pathway in a manner that a migraine headache
may develop in susceptible individuals remains to be re-
vealed. Several lines of evidence suggest that the periph-
eral trigeminal system is of pivotal importance in driving
the headache;
a. The referred pain patterns of migraine headache are
similar to the locations of referred pain after
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stimulation of meningeal and cerebral arteries, as
observed in awake patients during brain surgery
[116, 136–138]. The importance of these pain-
sensing structures is their vast innervation by
trigeminal fibres.
b. CGRP levels are increased during migraine
attacks. Blood samples from patients or animal
models during stimulation of the trigeminal fibres
suggest that the origin of the CGRP found in
migraine patients is indeed from the trigeminal
nerve [139–141]. CGRP is a potent vasodilator in
the periphery and a modulator of nociceptive
activity centrally. On second order neurons,
CGRP has no effect on spontaneous neuronal
firing but it can facilitate glutamatergic activity
and nociceptive activation [142–144].
c. Chemicals that do not cross, the otherwise intact,
blood-brain barrier (BBB) in sufferers [145–147],
such as CGRP and histamine, can trigger a migraine
attack [148, 149]. It is worth pointing out that the
origin of the pain is not vasodilation as originally
thought, as the migraine headache is not associated
with cerebral or meningeal vasodilation [150], and
hence anti-migraine treatments may not require
vasoconstrictor properties. Additionally, healthy
controls are not susceptible (or respond to a much
lower degree) to migraine headache following
provocation with such chemicals, suggesting that
the trigeminal system in migraine patients is
sensitized.
d. Effective migraine treatments, like the hydrophilic
sumatriptan, the large monoclonal antibodies
against the CGRP system and the peripherally
injected botulinum toxin [151–153], do not cross
the BBB. Hence, any direct or indirect mechanism
of action involves the peripheral trigeminal fibres
and the trigeminal ganglion that are outside the
BBB [154].
The above evidence, do not suggest that the peripheral
arm of the trigeminal system is the cause of migraine,
but demonstrate an important role for the peripheral tri-
geminal system in migraine headache. This evidence fur-
ther suggests that treatments that can block activation of
this system could be effective in suppressing migraine,
but not necessarily the generator of migraine attacks.
The trigeminal system, as well as, the trigemino-
thalamic pathway in the CNS, are excitatory pathways,
with glutamate being the major excitatory neurotrans-
mitter [120]. An ideal treatment for migraine would
block the glutamatergic transmission along these path-
ways, as this will inhibit painful signals reaching pain
processing cortical centres. However, central glutamater-
gic blockade is challenging due to severe adverse events
Fig. 2 Migraine pathophysiology involves activation of the hypothalamic region during the early premonitory phase, and activation of the
trigeminal system during the headache phase. Cortical spreading depression (CSD) is thought to be the biological process of the migraine aura.
How activation of the hypothalamus may lead to the development of CSD and activation of the trigeminal system remains unknown. Potentially
the hypothalamus may activate direct or indirect pathways involving other brain areas, such us the brainstem, or the parasympathetic system,
leading to the development of migraine aura and activation of the ascending trigeminothalamic pathway
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that can develop by inhibiting glutamatergic transmis-
sion, although not impossible [72, 118]. Peripherally act-
ing glutamate agonists and antagonists may offer a more
promising treatment approach [155, 156].
Vascular changes in migraine Vascular changes in mi-
graine were for a long time considered the driver of
migraine pain. In 1940 Ray and Wolff reported that
stimulation or distension of the large cranial arteries
evoked head pain associated with nausea [116]. Disten-
tion of the distal internal carotid artery and middle cere-
bral artery during balloon inflation in patients with
intracerebral arteriovenous malformations, can induce
focal headache [157]. Several studies attempted to ana-
lyse the role of the dural vasodilation by measuring
blood vessel diameter during an attack. A 3 T magnetic
resonance angiography (MRA) study during a spontan-
eous migraine attack showed no significant changes of
the diameter of middle meningeal artery (MMA) during
a spontaneous migraine attack [158], however a larger
study in cilostazol-induced migraine attacks, found that
the onset of migraine is associated with increase in
MMA circumference specific to the headache side [159].
In different studies in migraine patients with unilateral
headache, headache was associated with intracranial
dilatation of the middle cerebral artery (MCA) on the
painful side, which was normalised after treatment with
sumatriptan [160], as well as, with dilatation of the tem-
poral artery [161]. Spontaneous dilatation alone cannot
explain migraine pain, as arteries may dilate markedly,
such as during blood pressure decreases, without induc-
tion of a migraine attack. In a nitroglycerin-triggered mi-
graine study, peak dilation of the MCA occurred during
the infusion phase of nitroglycerin. However, a migraine
attack fulfilling the International Headache Society
diagnostic criteria occurred ~ 5 h post infusion, suggest-
ing a role of the cGMP pathway in the development of a
migraine attack, rather than the vasodilation itself. These
evidences suggest that mechanical dilatation is not
adequate to activate nociceptors and cause migraine
headache [162], and indeed, migraine can be induced,
e.g. by sildenafil, without initial dilatation of the middle
cerebral artery [163].
While it may be reasonable at this point to discard
vasodilation as a direct cause of migraine, more studies
are needed before eliminating blood vessels from the list
of factors contributing to the pathophysiology of
migraine. Both normal and pathological events occurring
within and between vascular cells could mediate bi-
directional communication between vessels and the
nervous system, without the need for changes in vascular
tone [164]. Blood vessels consist of a variety of cell types
that both release and respond to numerous mediators in-
cluding growth factors, cytokines, adenosine triphosphate
(ATP), and nitric oxide (NO), many of which can sensitize
trigeminal neurons. In addition, the majority of genomic
loci identified in GWAS to be associated with migraine
without aura are involved in pathways associated with vas-
cular function [20, 23]. Hence, it could still be possible
that blood vessels play a role in migraine pathophysiology
in the absence of vasodilation.
The postdrome phase
About 80% of migraine patients report at least one non-
headache symptom following the end of their headache,
while the disability scores remain high [69]. The mi-
graine postdrome is the least studied and least under-
stood phase of migraine. Only recently, functional
imaging showed widespread reduction in brain-blood
flow in the postdrome, but at least some persistent blood
flow increase in the occipital cortex [78, 165].
The evolutive process of migraine chronification
Chronic migraine (CM) is a disabling, underdiagnosed
and undertreated disorder, affecting ~ 1–2% of the gen-
eral population [166, 167]. Progression from episodic to
chronic migraine is a clinical reality [168, 169]. Studies
show that each year 2.5% of episodic migraine patients
progress into chronic migraine [170] which appears as a
distinct entity in the classification of the International
Headache Society (chronic migraine > 15 migraine days
per month) [68]. The nosology of CM has several clinical
implications, including the elimination of modifiable risk
factors and the therapeutic preventive options for CM
patients.
Patients with chronic migraine, have a significantly
higher incidence of positive family history of migraine,
menstrual aggravation of migraine, identifiable trigger
factors, associated symptoms, and early morning awak-
ening with headache [171]. A number of risk factors
have been identified to double the risk for migraine
chronification [172], including de novo increased mi-
graine attack frequency and overuse of acute migraine
medications [173–175], ineffective acute treatment that
could lead to medication overuse [176], depression
[177], which is a common comorbidity of migraine, and
lifestyle factors such as stress, high caffeine intake and
obesity [173, 178].
Certainly, either genetic factors or the presence of CM
itself, induce functional and plastic changes in the brain
of patients. In a recent resting-state fMRI study in
chronic migraine patients without medication overuse it
was shown that CM can progressively induce modifica-
tions in the CNS including large-scale reorganisation of
functional cortical networks and interactive neuronal
networks including the default mode network, the ex-
ecutive control network and the dorsal attention system
[179]. These are interesting outcomes as CM can impair
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the attention network resulting in impairment in execu-
tive functions [179]. Additionally, a number of brain im-
aging studies showed changes in gray matter volume, as
well as in white matter hyperintensities in CM patients,
compared to episodic patients [180–184]. Whether such
structural changes have any potential functional conse-
quences remains unknow.
The physiological mechanisms that underlie the devel-
opment of chronic migraine from its episodic form are
not understood. Cortical excitability appears to be ab-
normal in chronic migraine patients, but this could be a
consequence of the disease and not a driver of the
chronification [185, 186]. Here we will discuss the role
of inflammation and central sensitization in the evolutive
process of chronic migraine.
Inflammation and central sensitization in the
pathophysiology of migraine chronification
The question whether inflammation could contribute in
the activation of the trigeminal system in a manner that
could drive the migraine headache and be implicated in
the evolutive process of migraine chronification remains
relevant in migraine pathophysiology and treatment
[187]. Indeed, the broad use of non-steroidal anti-
inflammatory drugs for the acute treatment of headache
supports the involvement of some neuroimmune re-
sponses in the development of migraine [188, 189], while
steroid injections in the region of the greater occipital
nerve, are widely used as a preventive method in chronic
migraine [190, 191].
In animals, sustained CGRP release may induce per-
ipheral sensitization [192] likely due to release of inflam-
matory mediators (bradykinin, prostaglandins, etc.) from
nerve endings and cells of immune system [193–195].
During a migraine attack that can last for up to 72 h, the
levels of the neuropeptide CGRP is increased [139]. This
leads to continuous activation of C-fibers because they
store CGRP and of Aδ-fibers which contains CGRP re-
ceptors. This activation may lead to production and re-
lease of inflammatory cytokines, not only in the dura,
but possibly also in neuronal cell bodies, which are local-
ized in the TG. In addition, there are CGRP receptors
on ganglion cells [196]. Indeed, cytokines and chemo-
kines may be released by neurons, microglia, astrocytes,
macrophages and T cells, and activate pain neurons dir-
ectly via activation of non-neuronal cells, depending on
the expression of their receptors.
Major cytokines have been implicated in the pathway
resulting in neurogenic inflammation, including tumor
necrosis factor (TNF)-α, IL-1β and IL-6 [197]. TNF-α, a
potential pain mediators in neurovascular inflammatory
condition, has been suggested to be involved in the initi-
ation and progression of a migraine attack [198]. Studies
have demonstrated changes in plasma, serum, or urine
levels of TNF-α in migraine patients during attacks and
attack free intervals [199, 200]. Franceschini and co-
workers reported that mRNA expression of TNF-α in-
creased following migraine induction in animal models
[201]. Elevated TNF-α serum levels in humans, even in
outside of attacks, confirm a possible role of TNF-α in
migraine [202]. A direct pathogenic role of TNF-α has
not been reported during the use of this antibody in RA
or MC/UC. Considering the very high prevalence of mi-
graine, several hundred-thousand migraine patients must
have received TNF-α antibody but there are no reports
on any prevention of migraine attacks, not even in case-
reports. This suggests that preventing TNF-α inflamma-
tion is not a viable anti-migraine target.
Although strong and direct trigeminal stimulation
causes release of CGRP and substance P which may lead
to neurogenic inflammation in animal models (reviewed
by [198], it appears to have minor impact in acute mi-
graine. In the line of the hypothesis that continued
stimulation of both C-fibers and Aδ-fibers can cause TG
inflammation and hence be implicated in chronification,
this has been studied to some extent experimentally; (i)
In cultured trigeminal neurons, with focus on the in-
flammatory pathways [203, 204]. (ii) Administered CFA
(Complete Freunds’ Adjuvant) into the temporoman-
dibular joint (TMJ), which elicited activation of trigemi-
nal ganglion (TG) neurons [205]. (iii) Trigeminal
activation using chemical stimulation of the dura mater
with CFA, to test whether application of CFA on the
surface of the dura mater can cause long-term activation
of the TG, serving as a model of migraine chronification
[206] and activation of the trigeminal nucleus caudalis
leading to central sensitization [207].
The above experiments suggest that inflammation in-
deed could activate TG. Using culture of isolated trigem-
inal neurons as a model for studies of neurons and glial
cells, reportedly there was enhanced expression of
CGRP, and of the mitogen-activated protein (MAP)
kinase both in neurons and in SGCs following inflamma-
tion. The activation of a MAP kinase–dependent inflam-
matory signal pathway is involved in over-expression of
CGRP in nociceptive neurons and could participate in
generating pain hypersensitivity [208]. Looking further
into in vivo inflammation, administration of CFA into
the TMJ, elicits activation of TG by increased expression
of pERK1/2, pp38, CaMKII, NF-κB and DREAM after 2
and 10 days. Local inflammation in the TMJ, induced by
CFA, results in an upstream inflammation response in
the TG where the TMJ sensory fibers have their cell
bodies. Interestingly, this involves both neurons and
SGCs which together represent one anatomical and
functional unit [205].
Local inflammation of dura mater can induce inflamma-
tory activation in the TG. Application of inflammatory
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soup (IS) [209, 210], or CFA onto the dural surface in-
duced changes in the expression of pERK1/2, IL-1β and
CGRP positive nerve fibers in the TG illustrating that the
application of inflammatory substances onto the dura
mater could be used as an animal model for long term ac-
tivation of the trigeminovascular system [206]. Application
of CFA also induced activation (increased expression of c-
Fos) of the central part of the trigemino-vascular system:
the TNC and C1-C2 regions of the spinal cord [207]. Inter-
estingly, the inflammation could be blocked by the admin-
istration of a kynurenic acid analogue (SZR72), precursor
of a glutamatergic antagonist and an anti-inflammatory
substance [207, 211]. All the above evidence suggest that
inflammation can be responsible for the development of
at least peripheral sensitization that could then lead to the
development of central sensitization.
The concept of central sensitization is relevant not
only for the development of chronic migraine, but also
for the development of any chronic pain condition. In-
creased nociceptive processing, particularly due to the
development of peripheral sensitization that could occur
if indeed the trigeminal system is sustainably activated
during migraine attacks, could lead to the development
of central sensitization. Studies looking at biomarkers of
functions of the trigeminal and autonomic systems iden-
tified important differences in the interictal state of
chronic migraineurs compared to the interictal period of
episodic migraineurs, suggesting a higher level of interic-
tal activity of the trigeminal and cranial autonomic sys-
tem in chronic migraineurs [172]. In particular, interictal
levels of CGRP and vasoactive intestinal peptide (VIP)
are higher in chronic than in episodic migraine [212–
214]. Additionally, in animal models it has been demon-
strated that chronic exposure to triptans could lead to
the development of sensitization [215].
Central sensitization refers to altered behavioural of
second order neurons and even of third order thalamic
neurons, and is characterized by increased excitability,
increase synaptic strength and enlargement of their re-
ceptive fields [216–218]. Clinically, central sensitization
is manifested as a state of either hyperalgesia- an exag-
gerated pain in response to a stimulus that normally
causes mild pain, or allodynia- a pain response to a nor-
mally non painful stimulus, and exaggerated pain re-
sponse referred outside the original pain site [219].
These persistent sensory responses to noxious stimuli
and long-lasting synaptic plasticity at spinal and
supraspinal levels could be providing the neuronal basis
for persistent pain and “pain memory” in chronic mi-
graine [220–222]. Central sensitization is a glutamate-
dependent process and at least, NMDA receptor activa-
tion seems to be pivotal for the induction of central
sensitization in neuronal fibres innervating the dura
matter [223].
Indeed, during a migraine headache about 80% of mi-
graine patients develop cutaneous allodynia, charac-
terised by increased skin sensitivity, mostly within the
referred area of pain of the ipsilateral head [224, 225].
Stimulation of nociceptive afferent of the dura mater
leads to a sensitization of second-order neurons receiv-
ing cervical input [226]. About two thirds of the patients
developing cutaneous allodynia report that untreated mi-
graine attacks will result in a spread of allodynia to the
other side of the head or the forearm [224, 225], indicat-
ing the involvement of higher extra-trigeminal processes.
The limb or upper body allodynia seen in migraineurs,
and the extend of cutaneous allodynia could be due to
the development and spread of neuronal sensitization
from second order neurons in the TCC, to third order
neurons in the thalamus [219, 224]. Hence, repeated at-
tacks of peripheral and central sensitization could lead
to the development of chronic migraine.
Central sensitization is associated with abnormal neur-
onal hyperexcitability in the TCC, due to an increase of the
sensory inputs arriving from nociceptors on peripheral
trigeminal fibres that supply the affected area, which is a
consequence of peripheral sensitization [210]. Topical ap-
plication of inflammatory agents on the rat dura, which in-
duces long-lasting activation of the trigeminovascular
pathway [209, 227, 228], provokes long lasting sensitization
in trigeminocervical neurons that receive convergent inputs
from the intracranial dura and extracranial periorbital skin.
This neuronal sensitization is manifested as increased re-
sponsiveness to mechanical stimulation of the dura, to
mechanical and thermal stimulation of the skin, and expan-
sion of dura and cutaneous receptive fields [209]. These
changes are parallel to an increase of the extracellular glu-
tamate concentration of second order neurons in the TCC
[229], and suggest an important contribution of glutamate
and its receptors in allodynia [229].
Another factor that could contribute to the develop-
ment of central sensitization and the susceptibility in
developing chronic migraine could be a dysfunction in
pain modulating systems. An imbalance of pain
inhibition and facilitation could participate in the devel-
opment or maintenance of sensitization and could
contribute to the development of chronic migraine [230,
231]. What is interesting though, is that in at least 60–
70% of patients, CM can be blocked by treatments that
act peripherally at least on trigeminal fibres, such as the
newly developed mAbs against the CGRP system and
botulinum toxin. This further supports an important
role of the trigeminal system as peripheral sensory in-
puts are important in sustaining central drive in CM.
Conclusions
Migraine clinical and pathophysiological mechanisms
are not static and evolve continuously. During lifespan
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the clinical phenotype of migraine changes. These
changes may include transformation from episodic to
chronic migraine or even a disappearance of some or all
migraine symptoms all together. Genetic and epigenetic
susceptibility may be responsible for such changes, al-
though to date, studies failed to shed any light on how
such genetic alterations may be responsible for migraine
pathophysiology or any evolutive mechanism. On the
other hand, anatomical changes in the brain of a mi-
graine patient exist even from early childhood, but they
do not seem to have any functional consequences. The
causality dilemma of whether such changes are respon-
sible for how migraine evolves, or whether migraine
mechanisms drive these anatomic changes, remains to
be answered. Even in its episodic form, migraine is an
evolutive condition with different mechanisms involved
in the evolutive process of a migraine attack. These
mechanisms include hypothalamic alterations during the
premonitory phase, cortical excitability in the aura
phase, activation of the ascending trigeminothalamic
pain pathway with an involvement of the peripheral tri-
geminal arm during the headache phase, and potential
cortical changes during the postdrome phase. How mi-
graine headache is triggered following hypothalamic acti-
vation remains unknown. A potential involvement of the
parasympathetic pathway is possible, as it could be influ-
enced by hypothalamic changes and in turn activate the
trigeminal system through the trigemino-autonomic arc.
Such a mechanisms could explain activation of the per-
ipheral trigeminal system from a brain-initiated event.
The mechanisms that underlie the development of
chronic migraine from its episodic form are not well
understood. Several factors have been identified to in-
crease the risk for migraine chronification. Inflammation
and central sensitization play a significant role in the
evolutive mechanisms of chronic migraine.
The continuous changes in migraine phenotype and
pathophysiology during a migraine attack between epi-
sodic and chronic migraine and during the patient life-
span, make migraine, even in its episodic form, a
chronic evolutive disease.
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